{"quote": {"result": [{"language": "en-US", "region": "US", "quoteType": "EQUITY", "typeDisp": "Equity", "quoteSourceName": "Delayed Quote", "triggerable": false, "customPriceAlertConfidence": "LOW", "currency": "JPY", "esgPopulated": false, "market": "jp_market", "longName": "RaQualia Pharma Inc.", "marketState": "CLOSED", "regularMarketPrice": 794.0, "messageBoardId": "finmb_46479252", "exchange": "JPX", "shortName": "RAQUALIA PHARMA INC", "exchangeTimezoneShortName": "JST", "exchangeTimezoneName": "Asia/Tokyo", "regularMarketChangePercent": -0.8739077, "gmtOffSetMilliseconds": 32400000, "fiftyTwoWeekLowChange": 151.0, "fiftyTwoWeekLowChangePercent": 0.2348367, "fiftyTwoWeekRange": "643.0 - 1421.0", "fiftyTwoWeekHighChange": -627.0, "fiftyTwoWeekHighChangePercent": -0.44123855, "fiftyTwoWeekLow": 643.0, "fiftyTwoWeekHigh": 1421.0, "earningsTimestamp": 1684134000, "earningsTimestampStart": 1684134000, "earningsTimestampEnd": 1684134000, "trailingAnnualDividendRate": 0.0, "trailingPE": 22.928097, "trailingAnnualDividendYield": 0.0, "epsTrailingTwelveMonths": 34.63, "epsForward": 41.8, "firstTradeDateMilliseconds": 1311120000000, "priceHint": 2, "regularMarketChange": -7.0, "regularMarketTime": 1683872101, "regularMarketDayHigh": 804.0, "regularMarketDayRange": "792.0 - 804.0", "regularMarketDayLow": 792.0, "regularMarketVolume": 97000, "regularMarketPreviousClose": 801.0, "bid": 793.0, "ask": 795.0, "bidSize": 0, "askSize": 0, "fullExchangeName": "Tokyo", "financialCurrency": "JPY", "regularMarketOpen": 801.0, "averageDailyVolume3Month": 119706, "averageDailyVolume10Day": 81250, "sharesOutstanding": 21602600, "bookValue": 262.047, "fiftyDayAverage": 834.1, "fiftyDayAverageChange": -40.099976, "fiftyDayAverageChangePercent": -0.048075743, "twoHundredDayAverage": 1023.92, "twoHundredDayAverageChange": -229.91998, "twoHundredDayAverageChangePercent": -0.22454879, "marketCap": 17152464896, "forwardPE": 18.995216, "priceToBook": 3.029991, "sourceInterval": 15, "exchangeDataDelayedBy": 20, "tradeable": false, "cryptoTradeable": false, "symbol": "4579.T"}], "error": null}, "summary": {"result": [{"assetProfile": {"address1": "Meieki Southside Square", "address2": "8th Floor 1-21-19 Meieki Minami Nakamura-ku", "city": "Nagoya", "zip": "450-0003", "country": "Japan", "phone": "81 52 446 6100", "website": "https://www.raqualia.co.jp", "industry": "Biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "RaQualia Pharma Inc. engages in the research and development of pharmaceutical compounds worldwide. Its human products portfolio includes tegoprazan for gastroesophageal reflux disease, which is in phase 1 clinical trial in the United States; and grapiprant for pain management, which is in phase II clinical trial in the United States and phase I clinical trial in China, as well as in phase I clinical trial in China and the United States to treat cancer. The company also provides veterinary products such as, grapiprant for osteoarthritis in dogs; ghrelin receptor agonist to treat cancer-related anorexia/cachexia syndrome, and constipation resulting from spinal cord injury; and ELURA, a drug for the management of weight loss in cats with chronic kidney disease. In addition, it provides TRPM8 blocker for the target indication of neuropathic pain; motilin receptor agonist to treat gastrointestinal dysmotility, including gastroparesis, functional dyspepsia, and post-operative ileus; potassium-competitive acid blocker to treat gastro-esophageal reflux disease that has completed phase 1 clinical trial; 5-HT4 partial agonist to treat gastroparesis, functional dyspepsia, and chronic constipation; 5-HT2B antagonist to treat irritable bowel syndrome with diarrhea; EP4 antagonist, a pain management drugs for dogs; serotonin 5-HT2A and dopamine D2 receptor blocker to treat schizophrenia; EP4 antagonist to treat cancer that is in phase I clinical trial, as well as in phase 1 clinical trial for the indication of pain; Cyclooxygenase-2 inhibitor, Phase I clinical trials for the indication of pain; CB2 agonist; selective sodium channel blocker; P2X7 receptor antagonist, which is in Phase I clinical trials for the target indication of neuropathic pain; and retinoic acid receptor alpha agonist. It has a collaborative agreement with Interprotein Corporation, ASKA Pharmaceutical. Co., Ltd., and Epigeneron, Inc. The company was incorporated in 2008 and is headquartered in Nagoya, Japan.", "fullTimeEmployees": 65, "companyOfficers": [{"maxAge": 1, "name": "Mr. Hirobumi  Takeuchi", "age": 51, "title": "Pres & Representative Director", "yearBorn": 1971, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Hidefumi  Sugiyama", "title": "Gen. Mang. of Fin. & Accounting Department", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Masaki  Sudo", "title": "Exec. Officer & Director", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Katsuhiro  Uto", "title": "Exec. Officer & Director", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}], "maxAge": 86400}}], "error": null}}